Opendata, web and dolomites
H2020 projects about "pd"
The page lists 132 projects related to the topic "pd".
| # | |||
|---|---|---|---|
| 1 | FAIR-PARK-II | Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone | 2015 |
| 2 | PROPAG-AGEING | The continuum between healthy ageing and idiopathic Parkinson Disease within a propagation perspective of inflammation and damage: the search for new diagnostic, prognostic and therapeutic targets | 2015 |
| 3 | MoTriColor | Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) | 2015 |
| 4 | PD_manager | mhealth platform for Parkinson’s disease management | 2015 |
| 5 | PROPHETIC | PROPHETIC:An innovating Personal Healthcare Service for a holistic remote management and treatment of Parkinson patients. | 2015 |
| 6 | SynChI | Striatal cholinergic cell assemblies in movement disorders | 2015 |
| 7 | MitSyn | Alpha-synuclein and mitochondrial dysfunction: key links between Gaucher’s disease and Parkinson’s? | 2015 |
| 8 | CircaDopamine | The Role of Dopamine in the Regulation of Sleep and Circadian Rhythms | 2015 |
| 9 | QTMODEM | Quantitative Motor Control for Decision Making | 2016 |
| 10 | Amine-FUNC | Amine-Directed Diverse C(sp3)-H Functionalization | 2015 |
| 11 | MELANOPARK | Investigating the LRRK2-melanin connection through phosphoproteomics of isogenic melanoma cells | 2015 |
| 12 | RECOLOR | Regulation and consequences of LRRK2 phosphorylation,a path to Parkinson’s disease therapy and diagnostics | 2015 |
| 13 | eADAM | Ultra-small electrochemical aptasensors for specific dopamine real-time monitoring | 2016 |
| 14 | ROSNPD | Selective vulnerability of neuronal degeneration in Parkinson’s disease: the load of routine behaviour | 2016 |
| 15 | NEUMARQ | Neurodegenerative disease biomarkers based on high quality wireless EEG. | 2015 |
| 16 | PARK-IT | Unobtrusive, continuous and quantitative assessment of Parkinson’s disease: hard evidence for optimal disease management with information technologies | 2015 |
| 17 | APESA | Advanced Pump Engineering for Severe Applications | 2015 |
| 18 | DBSModel | Multiscale Modelling of the Neuromuscular System for Closed Loop Deep Brain Stimulation | 2015 |
| 19 | PROGSY | Prosaposin and GPR37 in synucleinopathies | 2015 |
| 20 | UPR NEURO | The Unfolded Protein Response in Neurodegeneration | 2015 |
| 21 | NoNoMeCat | Non-Noble Metal Catalysis - NoNoMeCat | 2016 |
| 22 | BrainMatTrain | Development of Biomaterial-based Delivery Systems for Parkinson’s disease - an Integrated Pan-European Approach | 2016 |
| 23 | Biomarkers for PD | Validation of diagnostic and prognostic biomarkers for Parkinson disease | 2015 |
| 24 | MAGNEURON | Hijacking cell signalling pathways with magnetic nanoactuators for remote-controlled stemcell therapies of neurodegenerative disorders | 2016 |
| 25 | SMART | SMART: Small Medicines Advanced Research Training | 2016 |
| 26 | i-PROGNOSIS | Intelligent Parkinson eaRly detectiOn Guiding NOvel Supportive InterventionS | 2016 |
| 27 | SysMedPD | Systems Medicine of Mitochondrial Parkinson’s Disease | 2015 |
| 28 | CENTRE-PD | TWINNING for a Comprehensive Clinical Centre for the Diagnosis and Treatment of Parkinson's Disease | 2016 |
| 29 | Subfailtec | Operation Optimization and Improved Reliability Solution for Electrical Substations | 2016 |
| 30 | LATE-STAGE | Palladium catalyzed C(sp3)‒H late-stage diversification of biologically active molecules | 2016 |
| 31 | IFNBetaMito | Role of IFN-β in mitochondrial homeostasis and impact on Parkinson Disease | 2016 |
| 32 | ClusterDynamics | Characterising the dynamical properties of size-selected supported metal clusters | 2017 |
| 33 | EVOL-WNS | Genetic factors contributing to White Nose Syndrome tolerance in North American and European Myotis-bats | 2016 |
| 34 | AVISSO | Audiovisual Speech Segmentation and Oscillations | 2016 |
| 35 | CatalApp | Copper Catalysis Applications | 2016 |
| 36 | Neurotoxic | An Ultra-sensitive Assay to Measure Oligomer Induced Toxicity in Human Cerebrospinal Fluid | 2016 |
| 37 | RADIcAL | Non-invasive rapid assessment of chronic liver disease using Magnetic Resonance Imaging with LiverMultiScan | 2016 |
| 38 | SYNDEGEN | Synaptic dysfunction in Neurodegenerative Diseases | 2017 |
| 39 | TheraPD | TheraPD: Smart and safer automated peritoneal dialysis by means of sterile connectivity, bio-sensors control systems and more biocompatible solutions for preventing rapid degradation of peritoneal mem | 2016 |
| 40 | BITCAT | Blocking Inhibition of T-cell Co-stimulation for Anti-tumour Therapy | 2017 |
| 41 | MADIA | Magnetic DIagnostic Assay for neurodegenerative diseases | 2017 |
| 42 | toxiclipasyn | Understanding the balance between functional and deleterious interactions of alpha-synuclein with lipid bilayers | 2017 |
| 43 | Smart-4-Fabry | Smart multifunctional GLA-nanoformulation for Fabry disease | 2017 |
| 44 | SUPRACOP | Systems Chemistry Approach towards Semiconductive Supramolecular Copolymers with Homo- and Heterometallophilic Interactions | 2017 |
| 45 | TreatER | Clinical study in Parkinson's disease with two unique goals: 1) Proof-of-concept of CDNF protein for disease modification; 2) Validation of clinically tested device for intracerebral drug delivery | 2017 |
| 46 | WEAKID | Clinical validation of miniature wearable dialysis machine | 2017 |
| 47 | TORPEDO | Understanding the molecular mechanisms controlling the orientation of plant cell divisions | 2017 |
| 48 | PDClungSME1 | A therapeutic vaccine candidate for lung cancer based on an exclusive cell line of Plasmacytoid Dendritic Cells (PDC*line) | 2016 |
| 49 | CATLIGCAR | Designing Novel Efficient Catalytic Strategies for the Transformation of Lignocellulose into Lignin-derived Chemicals and Valorisable Carbohydrates | 2017 |
| 50 | GLIOMA | Targeting Glioblastoma using Combinatorial Therapeutic Nanovaccine | 2017 |
| 51 | HOPESEE | How do pathogens exploit the symplast to promote disease? | 2017 |
| 52 | PARK-IT 2.0 | Unobtrusive, Continuous and Quantitative Assessment of Parkinson’s disease: Hard Evidence for Optimal Disease Management with Information Technologies | 2017 |
| 53 | INTERCELLAR | The role of the symplast in host-pathogen interactions – how does the symplastic, intercellular exchange of molecules regulate the outcomes of defence and infection? | 2017 |
| 54 | CALCEAM | Cooperative Acceptor Ligands for Catalysis with Earth-Abundant Metals | 2017 |
| 55 | CD4CRISPR | A quorum sensing mechanism regulating CD4 T cell proliferation | 2017 |
| 56 | Motivageing | Motivation–cognition interaction in healthy ageing and Parkinson’s disease | 2018 |
| 57 | BLMs 4 TB | Beta-lactams for Tuberculosis Treatment | 2018 |
| 58 | TIGITtherapy | TIGIT therapy for cancer treatment | 2017 |
| 59 | ImmuneCheckpointsAD | Immune checkpoint blockade for fighting Alzheimer’s disease | 2017 |
| 60 | EuroNeurotrophin | A European training network for the discovery of neurotrophins small molecule mimetics as candidate therapeutic agents for neurodegeneration and neuroinflammation | 2018 |
| 61 | PD UpReg | Gene knock-up via 3’UTR targeting to treat Parkinson’s disease | 2017 |
| 62 | STARDUST | in vivo optogeneticS, elecTrophysiology and phArmacology with an ultRasonically-powered DUST for Parkinson's Disease | 2017 |
| 63 | EXTEND | Bidirectional Hyper-Connected Neural System | 2018 |
| 64 | SENSIT | Sensitivity of human tumors to T cell attack | 2017 |
| 65 | Tremipen | The first simple monitoring device for Parkinson and other Tremor diseases | 2017 |
| 66 | NeuroPsyCAD | Artificial Intelligence for early and accurate neuropsychiatric diagnosis | 2017 |
| 67 | ECO-ZEN | Enabling Catalytic Cross Couplings with only Zinc Electrophiles, Nucleophiles and Boranes | 2018 |
| 68 | IMMUNOMARK | Omics integration for precision cancer immunotherapy | 2018 |
| 69 | NOMTGCS | Noble Metal Loaded Oxygen-deficient Mesoporous Tungsten Trioxide for Green Catalysis under Solar Light | 2019 |
| 70 | Alpha-Synuclein | Blocking the prion-like disease propagation in Parkinson’s disease and related disorders – model development and identification of cell-autonomous and cell non-autonomous factors. | 2019 |
| 71 | BRIDGING | The function of membrane tethering in plant intercellular communication | 2018 |
| 72 | TrueBrainConnect | Advancing the non-invasive assessment of brain communication in neurological disease | 2019 |
| 73 | gaitDCODE | Decoding impairments of gait and balance from local field potentials in patients with Parkinson's disease. | 2018 |
| 74 | TOLKEDA | Modulating brain structural plasticity versus neurodegeneration via a novel mechanism involving neurotrophins and dopamine, Tolls and Kek truncated-Trk-like receptors in Drosophila. | 2018 |
| 75 | InTheMLLrBALL | Innovative Therapeutic Strategies for Mixed Lineage Leukemia-rearranged B-cell Acute Lymphoblastic Leukemia | 2018 |
| 76 | MITOPOMPE | Targeting mitochondrial defects and oxidative stress in Pompe Disease: from pathogenesis to therapy | 2019 |
| 77 | Gut_Fights_PD | Investigating protective mechanisms of gut bacteria in C. elegans models of Parkinson’s disease | 2019 |
| 78 | CORLID | Cortical markers of L-DOPA-induced dyskinesias | 2019 |
| 79 | NANOBOTS | Tumor-Targeting Nanoengineered Bioorthogonal Technologies to Fight Metastatic Cancers | 2018 |
| 80 | MONMETAL | Generation of monolayer thin 2D nanosheets of noble/semi-noble metals: Investigation of their structural, electronic and catalytic properties | 2018 |
| 81 | IMI-PainCare | Improving the care of patients suffering from acute or chronic pain | 2018 |
| 82 | HOPE | Host Protective Engineering of Cancer Immunity by Targeting the Intracellular Immune Checkpoint NR2F6 | 2018 |
| 83 | BASILIC | Decoding at systems-level the crosstalk between the T cell antigen receptor, the CD28 costimulator and the PD-1 coinhibitor under physiological and pathological conditions. | 2018 |
| 84 | Gut_Fights_PD | Investigating protective mechanisms of gut bacteria in C. elegans models of Parkinson’s disease | 2019 |
| 85 | CC-Coupler | Integrated approach for environmentally benign C-C coupling reactions | 2018 |
| 86 | NeuroProtect | Novel Drug Therapy with Potential to Cure Neuro-Degenerative Diseases | 2018 |
| 87 | PET-AlphaSy | PET Imaging of Alpha-Synuclein Fibril Formation | 2018 |
| 88 | IMPROVE-PD | Identification and Management of Patients at Risk – Outcome and Vascular Events in Peritoneal Dialysis | 2019 |
| 89 | LPPDS | A portable peritoneal dialysis system for home use that monitors for infection | 2018 |
| 90 | TREAT-PD | Patient-specific treatment for Parkinson's disease using reprogrammed skin cells | 2018 |
| 91 | TERIPHIC | Fabrication and assembly automation of TERabit optical transceivers based on InP EML arrays and a Polymer Host platform for optical InterConnects up to 2 km and beyond | 2019 |
| 92 | IRL790 | NOVEL THERAPEUTIC FOR THE TREATMENT OF PARKINSONS DISEASE | 2018 |
| 93 | GONDOLA | Automated Mechanical Peripheral Stimulation for motor rehabilitation in people living with Parkinson’s Disease (PD) | 2018 |
| 94 | ChEESE | Centre of Excellence for Exascale in Solid Earth | 2018 |
| 95 | GyroGlove | Development and Commercialisation of an Intelligent Wearable Platforms to Stabilise Hand Tremors in Parkinson’s Disease and Essential Tremor | 2018 |
| 96 | PD_Pal | Palliative care in Parkinson’s disease | 2019 |
| 97 | FutureTrophicFactors | Elucidating therapeutic effects and mode of action of future trophic factorsin ALS and Parkinson’s disease | 2019 |
| 98 | VOILA | Validation of Innovative Lipopeptide Antibiotics | 2019 |
| 99 | SCAMPICITY | cAMP-dependend plasticity of striatal projection neurons in health and disease | 2019 |
| 100 | PD-MitoQUANT | PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease | 2019 |
| 101 | PARNANT | Pathogenetic pathways in age-related neurodegenerations as novel therapeutic targets for Parkinson’s disease | 2019 |
| 102 | PD-MIND | Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug | 2019 |
| 103 | THERAPE | Novel blood-brain barrier permeable CDNF-derived therapeutic peptides for the protection and regeneration of dopamine neurons | 2019 |
| 104 | emiT | ELECTROMAGNETIC TIME REVERSAL FOR ON-LINE PARTIAL DISCHARGE LOCATION IN TRANSMISSION AND DISTRIBUTION NETWORKS | 2019 |
| 105 | NITRATE | Nitrate Imbalance-control by TRAnsformative Technologies that are Electrochemically-driven | 2019 |
| 106 | UNPACK PD-L1 | Molecular mechanism and inhibition of extracellular vesicle-mediated PD-L1 release in melanoma cells | 2020 |
| 107 | TRIC-TB | Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments. | 2019 |
| 108 | T-NHL SUPRESSORS | Tumor suppressor pathways counteracting oncogenic immune receptor signaling in T-Cell Lymphoma | 2019 |
| 109 | VACCIBIOME | Cancer Vaccines and Gut Microbiome: a rational approach to optimize cancer immunotherapy | 2019 |
| 110 | TARGET SLEEP | Boosting motor learning through sleep and targeted memory reactivation in ageing and Parkinson’s disease | 2020 |
| 111 | MPT system | Innovative, cost-effective, ultra-compact MRI-guided therapy system for diagnosis and immediate treatment of Parkinson's Disease | 2019 |
| 112 | Warrick X1 | Safe home-based portable peritoneal dialysis system that offers simpler dialysis and improved quality of life for patients | 2019 |
| 113 | PD-Watch | Wearable technology for the selective detection and continuous monitoring of movement disorders related to Parkinson’s disease | 2019 |
| 114 | TeNDER | affecTive basEd iNtegrateD carE for betteR Quality of Life | 2019 |
| 115 | CATSO | New Catalytic Reactions using Sulfur Dioxide | 2020 |
| 116 | DBScontrol | Implementation and preclinical testing of a closed-loop control system for deep brain stimulation | 2020 |
| 117 | AND-PD | COMORBIDITY MECHANISMS OF ANXIETY AND PARKINSON’S DISEASE | 2020 |
| 118 | VANGUARD | New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes | 2020 |
| 119 | ERA4TB | EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS | 2020 |
| 120 | NSC-Reconstruct | Novel Strategies for Cell-based Neural Reconstruction | 2020 |
| 121 | DIANA | Organ-on-a-chip Drug screenIng device to tArget braiN diseAse | 2020 |
| 122 | ExpoBiome | Deciphering the impact of exposures from the gut microbiome-derived molecular complex in human health and disease | 2020 |
| 123 | TESTIMONY | Tumor Endothelial Cells: Gatekeepers Of Anti-Tumor Immunity | 2020 |
| 124 | ParkIFNAR | Soluble IFNAR2 in Parkinson's disease and its role in the regulation of IFNβ in a neuroinflammatory context. | 2020 |
| 125 | OXYGEN | The redox evolution of arc magmas: from the oxygenation of the Earth’s atmosphere to the genesis of giant hydrothermal ore deposits | 2020 |
| 126 | BMPARK | Development of BMP2 Neurotrophic Therapy for Parkinson’s Disease | 2020 |
| 127 | ADBCRZB | Atomically Dispersed Bifunctional Catalysts for Reversible Zn-CO2 Batteries | 2020 |
| 128 | COUPC1 | Coupling strategies for scavenging reactive C1 intermediates in hydrogen generation | 2020 |
| 129 | TMC4MPO | Transition metal carbides as efficient catalysts for methane partial oxidation | 2021 |
| 130 | CO2Polymerisation | Conversion of CO2/H2O to Polyethylene through Cascade Electro-reduction–Polymerisation Catalysis | 2020 |
| 131 | LySyT | Understanding the role of lysosomes in the intercellular TNT-mediated spreading of α-synuclein and the impact of lysosomal dysfunction | 2020 |
| 132 | HT4PD | The role of the serotonin 5-HT4 receptor in motor and non-motor symptoms of Parkinson’s disease | 2021 |